How Glucocorticoids Affect Cancer Cells
Author Information
Author(s): Aaron L. Miller, Anna S. Garza, Betty H. Johnson, E. Brad Thompson
Primary Institution: University of Texas Medical Branch
Hypothesis
Mitogen-activated protein kinases influence the ability of certain malignant lymphoid cells to undergo apoptosis when treated with glucocorticoids.
Conclusion
Inhibiting specific MAPKs can restore glucocorticoid sensitivity in resistant cancer cells.
Supporting Evidence
- Blocking JNK and ERK activity restored glucocorticoid sensitivity in resistant CEM cells.
- Forskolin and rapamycin treatments also increased sensitivity to glucocorticoids.
- Phosphorylation of the glucocorticoid receptor at serine 211 was enhanced by treatments that restored sensitivity.
Takeaway
Some cancer cells don't die when treated with certain drugs, but scientists found ways to make them sensitive again by blocking certain proteins.
Methodology
The study evaluated the effects of inhibiting MAPKs and stimulating the cAMP/PKA pathway on glucocorticoid sensitivity in human acute lymphoblastic leukemia cells.
Potential Biases
Potential bias in the selection of cell lines and treatments used.
Limitations
The study primarily focused on specific cell lines, which may not represent all lymphoid malignancies.
Participant Demographics
Human acute lymphoblastic leukemia cell lines were used.
Statistical Information
P-Value
0.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website